Data Mining Technical Publications to Rank the Innovators in RNA Therapeutics
Specialists lead the RNA intellectual property ecosystem but may still need big pharma to bring new treatments to market making the space ripe for partnerships, mergers and acquisitions
- 2021 saw a significant jump in RNA based trials. Large sequencing projects and the success of mRNA COVID-19 vaccines should drive the growth of the global RNA therapeutics market.
- Our analysis suggests that Moderna Inc (MRNA US) , Vertex Pharmaceuticals (VRTX US), Incyte Corp (INCY US), Alnylam Pharmaceuticals (ALNY US), Ionis Pharmaceuticals (IONS US) lead in RNA therapy related innovations.
- R&D collaboration, licensing deals, strategic investments and buyouts between RNA specialists and big pharma will increase as sitting on the sidelines might no longer be an option.
Full analysis here:- https://www.smartkarma.com/insights/data-mining-technical-publications-to-rank-the-innovators-in-rna-therapeutics?utm_source=tiger_community
By Pyari Menon, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/pyari-menon?utm_source=tiger_community
On Thematic (Sector/Industry) - https://www.smartkarma.com/collections/thematic-strategy?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
.
.